Search
Vixarelimab
go.drugbank.com/drugs/DB16350InvestigationalVixarelimab is under investigation in clinical trial NCT03816891 (A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Prurigo Nodularis).
Onvansertib
go.drugbank.com/drugs/DB15110InvestigationalOnvansertib is under investigation in clinical trial NCT03303339 (Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML).).
Iseganan
go.drugbank.com/drugs/DB16010InvestigationalIseganan is under investigation in clinical trial NCT00022373 (Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer).
Gamgertamig
go.drugbank.com/drugs/DB22765InvestigationalOM336 is under investigation in clinical trial NCT07083960 (OM336 in Autoimmune Cytopenias).
Sulfisoxazole
go.drugbank.com/drugs/DB00263ApprovedVet approvedA short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms.
Synonyms: N'-(3,4)Dimethylisoxazol-5-yl-sulphanilamide, 4-Amino-N-(3,4-dimethyl-5-isoxazolyl)benzenesulfonamideAzlocillin
go.drugbank.com/drugs/DB01061ApprovedAzlocillin is a semisynthetic ampicillin-derived acylureido penicillin.
(4R)-limonene
go.drugbank.com/drugs/DB08921Investigationalin perfumery. … Limonene is common in cosmetic products.
Synonyms: (4R)-1-methyl-4-isopropenylcyclohex-1-eneSelenocysteine
go.drugbank.com/drugs/DB02345InvestigationalA naturally occurring amino acid in both eukaryotic and prokaryotic organisms. It is found in tRNAs and in the catalytic site of some enzymes.
Oxelumab
go.drugbank.com/drugs/DB16663InvestigationalOxelumab is under investigation in clinical trial NCT00983658 (A Study of HuMAb OX40L in the Prevention of Allergen-induced Airway Obstruction in Adults With Mild Allergic Asthma).
Elzovantinib
go.drugbank.com/drugs/DB18918InvestigationalElzovantinib is under investigation in clinical trial NCT03993873 (Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET).